![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Summit Therapeutics Inc | NASDAQ:SMMT | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.11% | 9.48 | 9.52 | 9.75 | 1,045 | 12:32:19 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2015
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F x FORM 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES ¨ NO x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On August 24, 2015, Summit Therapeutics plc (the Company) issued a press release announcing that it would announce its financial results for its second quarter ended July 31, 2015 on Thursday, August 27, 2015. A copy of this press release is attached as Exhibit 99.1 and incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||
By: | /s/ Erik Ostrowski | |
Erik Ostrowski | ||
Chief Financial Officer |
Date: August 25, 2015
EXHIBIT INDEX
Exhibit |
Description | |
99.1 | Press Release dated August 24, 2015 relating to Notice of Second Quarter Financial Results |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
SUMMIT THERAPEUTICS TO REPORT SECOND QUARTER 2015 FINANCIAL RESULTS ON 27 AUGUST 2015
Oxford, UK, 24 August 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its second quarter financial results for the period ending 31 July 2015 on Thursday, 27 August 2015.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EST. Conference call information will be included in the second quarter results press release and a replay of the call will also be available through the Companys website, www.summitplc.com.
- END -
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski (US office) |
Tel: +44 (0)1235 443 951 +1 617 294 6607 | |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 7148 7900 | |
N+1 Singer (Broker) Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 | |
MacDougall Biomedical Communications (US media contact) Michelle Avery |
Tel: +1 781 235 3060 mavery@macbiocom.com | |
Peckwater PR (Financial public relations, UK) Tarquin Edwards |
Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions